Clinical trials: Liver Cirrhosis With Acute Decompensation
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Cirrhosis, Acute Decompensation
Study of microRNAs in a Decompensated Cirrhosis
Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune responses. Septic complications represent a major issue in the management of cirrhotic patients, with a 1-month mortality rate of 23%…
- Trial name
- EmiC (NCT03905746)
- Testing
- blood sample at Day 0, blood sample at Day 2 and Day 7, stool sample at Day 0
- Where
- France
- Volunteers
- 444 people
- Sponsor
- Hospices Civils de Lyon
Liver Cirrhosis, Decompensated Cirrhosis of Liver
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the…
- Trial name
- PROSPECT (NCT06855056)
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 189 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard…
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Trial name
- NCT06987968
- Testing
- VS-01 on top of SOC (Active Treatment Group), SOC
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Genfit
Acute Decompensation in Liver Cirrhosis
Impact of Acute Decompensation in Patients of Cirrhosis With or Without Prior Decompensation
This a prospective observational study in Chronic Liver Disease patients admitted or seen in OPD, Department of Hepatology, Institute of Liver and Biliary Sciences, India.
- Trial name
- NCT03005587
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis With Acute Decompensation
Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures
Patients with liver cirrhosis have historically received prophylactic transfusions before invasive procedures with high risk of bleeding.
- Trial name
- PROTECT-CIRR (NCT07437755)
- Testing
- Blood Products transfusion
- Where
- Romania
- Volunteers
- 116 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
- Trial name
- CONTROL-ACLF (NCT07694297)
- Testing
- NTZ 500mg BID on top of SOC
- Volunteers
- 16 people
- Sponsor
- Genfit
Acute-On-Chronic Liver Failure, Ascites
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and…
- Trial name
- NCT05900050
- Testing
- VS-01 on top of SOC, SOC (Control Group)
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Genfit
Liver Cirrhosis With Acute Decompensation
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
The aim of this study is to assess prospectively the critical period prior to the development of Acute-on-Chronic Liver Failure (ACLF) (1), to uncover mechanistic and pathophysiological processes associated with the development…
- Trial name
- PREDICT (NCT03056612)
- Testing
- Observation protocol
- Where
- 45 sites in Austria, Belgium and 12 more
- Volunteers
- 1,314 people
- Sponsor
- Jonel Trebicka
Decompensated Cirrhosis
Efficacy of High Dose Albumin Therapy in Improving Liver Transplant-free Survival in Patients With Acute Decompensation of Cirrhosis
Research Objectives- We hypothesized high-dose 25% albumin would be superior to standard medical treatment in improving 3-month mortality in patients with acute decompensation of cirrhosis by improving the systemic hemodynamics…
- Trial name
- NCT05956197
- Testing
- No intervention
- Where
- India
- Volunteers
- 55 people
- Sponsor
- Institute of Liver and Biliary Sciences, India